Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.

CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. J Clin Oncol. 2013 Jul 20; 31(21):2753-5.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.